AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Morgan Stanley reduced its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) stock to $5.00 from $8.00 on Monday, while maintaining an Equalweight rating on the shares. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.11, though it faces profitability challenges with a -623% gross profit margin. The price target adjustment follows Recursion’s recent pipeline prioritizations, cost reductions, and updated cash burn guidance, according to the research firm. Morgan Stanley established a base case range of $3 to $7 for the biopharmaceutical company, which uses machine learning for drug discovery and development. The firm identified upcoming oncology and rare disease readouts in the second half of 2025 as the next significant inflection points for Recursion.
Morgan Stanley’s analysis reflects revised financial modeling for Recursion Pharmaceuticals following the company’s strategic adjustments to its research pipeline and operational expenses. In other recent news, Recursion Pharmaceuticals reported its Q1 2025 financial results, which slightly missed analysts’ estimates. The company posted earnings per share of -$0.5, compared to the forecast of -$0.49, and revenue of $14.75 million, falling short of the expected $14.98 million. Additionally, Recursion Pharmaceuticals has filed a prospectus supplement to register for resale approximately 4.26 million shares of its Class A common stock, issued to Tempus Labs as part of a Master Agreement. On the analyst front, BofA Securities revised its price target for Recursion Pharmaceuticals to $8.00 from $10.00, maintaining a Neutral rating, following the company’s decision to deprioritize four pipeline programs and suspend another clinical program.
A significant development for Recursion Pharmaceuticals is the release of Boltz-2, an open-source biomolecular model developed in collaboration with MIT. Boltz-2 is designed to enhance drug discovery processes by operating up to 1,000 times faster than current benchmarks. This model is expected to improve the accuracy of predicting molecular structures and binding affinities, crucial in drug development. Recursion’s partnerships are also advancing, with the company receiving an additional $7 million milestone payment from Sanofi (NASDAQ:SNY), part of a potential $300 million deal. The company’s strong cash position, with reserves of $509 million, is projected to support operations into mid-2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley
June 16, 2025 10:24 PM AEST | By EODHD
